These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34309184)

  • 1. A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites.
    Kawaratani H; Sawai H; Onishi M; Kogiso T; Shimada N; Uojima H; Nakajima T; Matsumoto N; Ikejima K; Ishikawa T; Terai S; Motoyama H; Komori A; Hirashima N; Saito S; Eguchi Y; Nojima M; Kawai Y; Tateyama M; Yoshiji H; Tanaka Y
    Liver Int; 2021 Dec; 41(12):2944-2953. PubMed ID: 34309184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
    Shigefuku R; Iwasa M; Eguchi A; Tempaku M; Tamai Y; Suzuki T; Takei Y
    Intern Med; 2021; 60(21):3359-3368. PubMed ID: 34719623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y
    Dig Dis; 2019; 37(3):239-246. PubMed ID: 30625470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.
    Kogiso T; Kobayashi M; Yamamoto K; Ikarashi Y; Kodama K; Taniai M; Torii N; Hashimoto E; Tokushige K
    Intern Med; 2017 Nov; 56(22):2993-3001. PubMed ID: 28943585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Sakaida I; Terai S; Nakajima K; Shibasaki Y; Tachikawa S; Tsubouchi H
    J Gastroenterol; 2017 Feb; 52(2):229-236. PubMed ID: 27379386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
    PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites.
    Arase Y; Kagawa T; Tsuruya K; Sato H; Teramura E; Anzai K; Hirose S; Deguchi R; Shiraishi K; Mine T
    Clin Drug Investig; 2019 Jan; 39(1):45-54. PubMed ID: 30284699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term administration of Tolvaptan to patients with decompensated cirrhosis.
    Kanayama K; Chiba T; Kobayashi K; Koroki K; Maruta S; Kanzaki H; Kusakabe Y; Saito T; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Yasui S; Kanda T; Maruyama H; Kato J; Kato N
    Int J Med Sci; 2020; 17(7):874-880. PubMed ID: 32308540
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.
    Sagawa E; Okubo H; Ando H; Sorin Y; Kanazawa R; Nakadera E; Fukada H; Kokubu S; Miyazaki A
    J Pharmacol Sci; 2019 Apr; 139(4):373-376. PubMed ID: 30857764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Chishina H; Hagiwara S; Nishida N; Ueshima K; Sakurai T; Ida H; Minami Y; Takita M; Kono M; Minami T; Iwanishi M; Umehara Y; Watanabe T; Komeda Y; Arizumi T; Kudo M
    Dig Dis; 2016; 34(6):659-664. PubMed ID: 27750234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    Sakaida I; Terai S; Kurosaki M; Okada M; Hirano T; Fukuta Y
    J Gastroenterol; 2020 Aug; 55(8):800-810. PubMed ID: 32388692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    Namba M; Hiramatsu A; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Tsuge M; Imamura M; Chayama K
    J Gastroenterol; 2020 Feb; 55(2):217-226. PubMed ID: 31485782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG
    BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan for difficult- to -treat ascites: Difficulties in opening doors for GWAS application.
    Singh S; Roy A
    Liver Int; 2021 Dec; 41(12):3033. PubMed ID: 34486803
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictors of tolvaptan short-term response in patients with refractory ascites: A meta-analysis.
    Bellos I; Kontzoglou K; Perrea DN
    J Gastroenterol Hepatol; 2020 Feb; 35(2):182-191. PubMed ID: 31323125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Okita K; Sakaida I; Okada M; Kaneko A; Chayama K; Kato M; Sata M; Yoshihara H; Ono N; Murawaki Y
    J Gastroenterol; 2010 Sep; 45(9):979-87. PubMed ID: 20387081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.
    Uojima H; Hidaka H; Nakayama T; Sung JH; Ichita C; Tokoro S; Masuda S; Sasaki A; Koizumi K; Egashira H; Kako M
    World J Gastroenterol; 2017 Dec; 23(45):8062-8072. PubMed ID: 29259382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.